KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Accured Expenses (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Change in Accured Expenses data on record, last reported at $5.1 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 455.68% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $3.0 million, up 303.22%, while the annual FY2025 figure was $3.0 million, 303.22% up from the prior year.
  • Change in Accured Expenses reached $5.1 million in Q4 2025 per AQST's latest filing, up from $118000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.1 million in Q4 2025 and bottomed at -$4.0 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$210050.0, with a median of $46500.0 recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 3916.0% in 2023, down 160.3% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.2 million in 2021, then crashed by 102.08% to -$25000.0 in 2022, then soared by 3916.0% to $954000.0 in 2023, then decreased by 3.98% to $916000.0 in 2024, then soared by 455.68% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $5.1 million in Q4 2025, $118000.0 in Q3 2025, and $600000.0 in Q2 2025.